Merrimack Pharmaceuticals Inc. and Cancer Treatment Centers Of America Partner in Multifaceted Collaboration to Advance Translational Research and Individualized Treatment

Published: Jun 29, 2012

CAMBRIDGE, Mass., June 28, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) and the Cancer Treatment Centers of America® (CTCA) announced today that they have formed a unique and wide ranging partnership to advance their long-term vision of individualized treatment - where diagnosis and therapy is guided by an in-depth understanding of the underlying mechanism of a patient's disease. The collaboration encompasses research on diagnostics based on a network signaling approach to analyzing patients' tumors as well as clinical trial research.

Back to news